Not Yet RecruitingNot Applicable

Real-World Treatment Patterns and Survival Outcomes in Patients With Intermediate-Stage Hepatocellular Carcinoma.

Egypt200 participantsStarted 2026-03

Plain-language summary

The goal of this observational study is to learn about the different treatment options for intermediate-stage hepatocellular carcinoma. The main question it aims to answer is: \- What are the survival outcomes among participants aged 18 or older who receive treatment for intermediate-stage hepatocellular carcinoma?

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Aged ≥18 years. * Both sexes. * Diagnosis of hepatocellular carcinoma based on accepted radiologic or histologic criteria. * Classified as intermediate stage (BCLC-B) at time of decision for first-line treatment. * Child-Pugh A or B. * ECOG performance status 0-1. Exclusion Criteria: * BCLC A, C, or D at diagnosis. * Prior curative therapy (resection, transplantation, curative ablation). * Missing essential data (imaging, liver function, treatment records). * Mixed HCC-cholangiocarcinoma.

What they're measuring

Overall Survival (OS)

Timeframe: From randomization to the end of treatment at 5 years.

Progression-Free Survival (PFS)

Timeframe: From randomization to the end of treatment at 5 years.

Objective response (mRECIST)

Timeframe: From randomization to the end of treatment at 5 years.

Adverse events (CTCAE)

Timeframe: From randomization to the end of treatment at 5 years.

Trial details

NCT IDNCT07449637

SponsorSohag University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-06

Contact for this trial

Mohammed Hamdy

+201101501551 mohammedzohry2018@gmail.com

View on ClinicalTrials.gov More BCLC Stage B Hepatocellular Carcinoma trials